http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Hwang, Chul-Min,Ishida, Masayoshi,Ito, Hiroshi,Maeda, Tetsuhiko,Nakano, Akihiro,Kato, Atsushi,Yoshida, Tetsuya The Korean Institute of Electrical Engineers 2012 The Journal of International Council on Electrical Vol.2 No.2
Polymer electrolyte-based unitized reversible fuel cells (URFCs) combine the functionality of a fuel cell and an electrolyzer in a single device. In this study, the influence of hydrophobic agent in the gas diffusion layer (GDL) of URFC was investigated. The titanium (Ti)-felt GDL which treated with different percent of PTFE emulsion was intensively tested with various humidification temperature conditions in the single cell of URFC. I-V performance curves and divided three overpotentials were compared and analyzed in the fuel cell mode. The electrolyzer performances were also evaluated with the I-V curves. Experimental results showed that the GDLs with high PTFE contents have better performance in the dry conditions. On the other hand, the increased PTFE contents accelerate flooding problem in the wet condition and it is related with rising concentration overpotential. The electrolyzer performances are almost same with different PTFE contents of GDL.
Shusuke Yagi,Ken-ichi Aihara,Masashi Akaike,Daiju Fukuda,Hotimah Masdan Salim,Masayoshi Ishida,Tomomi Matsuura,Takayuki Ise,Koji Yamaguchi,Takashi Iwase,Hirotsugu Yamada,Takeshi Soeki,Tetsuzo Wakatsuk 대한당뇨병학회 2015 Diabetes and Metabolism Journal Vol.39 No.4
Background: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment. Methods: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively. Results: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease. Conclusion: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.